ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 6 more changesShow less
    • Primary completion date changed from estimate of Jun 30, 2021 to Apr 14, 2022
    • Results posted: Sep 29, 2026
    • Trial completed
    • Final enrollment: 10 participants (planned 48)
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 2 of 4 entries
  2. Secondary endpoints: details revised at 2 of 4 entriesv9
  3. Secondary endpoints: details revised at 1 of 4 entriesv8
  4. Secondary endpoints: details revised at 4 of 4 entriesv7
  5. Primary completion date changed from estimate of Jun 30, 2021 to Apr 14, 2022v6 Show 10 more changesShow less
    • Start date: Aug 30, 2019 to Feb 18, 2020
    • Primary endpoint revised
    • Trial status: Recruiting to Completed
    • Enrollment target: estimated 48 to confirmed 10
    • Study completion date changed from estimate of Jun 30, 2023 to Apr 14, 2022
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints revised (4)
    • Study description shortened, about 78 words
    • Site details revised at 2 of 2 sites
    • Collaborators shortened, about 3 words
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Jan 1, 2021 to Jun 30, 2021
    • Study completion date: Jun 30, 2021 to Jun 30, 2023
    v5
  2. Study sites: 1 to 2v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 1, 2019 to Aug 30, 2019
    v3
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Abivax S.A.
8 trials monitored
See all monitored trials
Liver Cancer
1,602 trials monitored
See 70 trials at risk
Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Trial Details
NCT Number NCT03897543
Lead Sponsor Abivax S.A.
Conditions
(from sponsor)		 Carcinoma, Hepatocellular
Related terms Carcinoma, Hepatocellular
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov